María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
Novartis and the Gates Foundation Collaborate on Off-the-Shelf Gene Therapy for Sickle Cell Disease
Novartis and the Bill and Melinda Gates Foundation are collaborating on a one-step, one-time gene therapy for patients with sickle cell disease (SCD). The...
‘All of Us’ Technology Platform Aims to Democratize Research
All of Us, a $1.5 billion National Institutes of Health (NIH) initiative to collect DNA and health data on one million Americans from diverse...
FDA Accepts sNDA for Zanubrutinib in Waldenström Macroglobulinemia
The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for zanubrutinib for the treatment of adult patients with...
Crizotinib Approved for Relapsed/Refractory Systemic ALCL
Crizotinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children older than one year and young adults...
Daratumumab and Hyaluronidase-fihj Approved for Light Chain Amyloidosis
The combination of daratumumab and hyaluronidase-fihj and bortezomib, cyclophosphamide, and dexamethasone (D-VCd) was granted accelerated approval for the treatment of adults with newly diagnosed...
Current Issue
March 2021 Volume 7 Issue 4
This issue examines the 21st Century Cures Act’s information blocking requirements, blood services around the globe, and more.